Trial of Pregabalin for Acute and Chronic Sciatica

Abstract

BACKGROUND Sciatica can be disabling, and evidence regarding medical treatments is limited. Pregabalin is effective in the treatment of some types of neuropathic pain. This study examined whether pregabalin may reduce the intensity of sciatica. METHODS We conducted a randomized, double-blind, placebo-controlled trial of pregabalin in patients with sciatica. Patients were randomly assigned to receive either pregabalin at a dose of 150 mg per day that was adjusted to a maximum dose of 600 mg per day or matching placebo for up to 8 weeks. The primary outcome was the leg-pain intensity score on a 10-point scale (with 0 indicating no pain and 10 the worst possible pain) at week 8; the leg-pain intensity score was also evaluated at week 52, a secondary time point for the primary outcome. Secondary outcomes included the extent of disability, back-pain intensity, and quality-of-life measures at prespecified time points over the course of 1 year. RESULTS A total of 209 patients underwent randomization, of whom 108 received pregabalin and 101 received placebo; after randomization, 2 patients in the pregabalin group were determined to be ineligible and were excluded from the analyses. At week 8, the mean unadjusted leg-pain intensity score was 3.7 in the pregabalin group and 3.1 in the placebo group (adjusted mean difference, 0.5; 95% confidence interval [CI], −0.2 to 1.2; P = 0.19). At week 52, the mean unadjusted leg-pain intensity score was 3.4 in the pregabalin group and 3.0 in the placebo group (adjusted mean difference, 0.3; 95% CI, −0.5 to 1.0; P = 0.46). No significant between-group differences were observed with respect to any secondary outcome at either week 8 or week 52. A total of 227 adverse events were reported in the pregabalin group and 124 in the placebo group. Dizziness was more common in the pregabalin group than in the placebo group. CONCLUSIONS Treatment with pregabalin did not significantly reduce the intensity of leg pain associated with sciatica and did not significantly improve other outcomes, as compared with placebo, over the course of 8 weeks. The incidence of adverse events was significantly higher in the pregabalin group than in the placebo group.

Clinical Observation, Management and Function Of low back pain Relief Therapies (COMFORT): A cluster randomised controlled trial protocol

“…The medication diary has shown high concordance with clinically determined measures, for example, plasma drug concentrations and pill count or canister weight (kappa>0.6 in seven studies), 48 and high completion rates among participants was also reported with these diaries. 49…”

Placeboeffekte in wissenschaftlichen Studien

“…Bei der medikamentösen Behandlung von Rückenschmerzen wirken Placebos so gut wie Paracetamol © [9]. Bei einer Radikulopathie ist der Wirkstoff Pregabalin des Antiepileptikums Lyrica © nicht besser als ein Scheinmedikament [10]. Ein ähnliches Bild zeigt sich beim Beruhigungsmittel Diazepam © [11].…”

General practitioners’ decision-making process to prescribe pain medicines for low back pain: a qualitative study

“…3 4 Similarly, gabapentinoids are ineffective and potentially harmful for the management of LBP; however their use is increasing. [4][5][6] On the other hand, the use of pharmacological therapies that are recommended as first-line care such as NSAIDs has reduced 33% from 2004 to 2014. 3 In the USA, antidepressants are prescribed to about a quarter of patients…”